Nuo Therapeutics Q2 2026 revenue up >150% YoY; operating loss narrows to $167K

Nuo Therapeutics, Inc.

Q2 2026 total revenues ~$1.77M, up >150% YoY; H1 2026 revenues ~$3.07M, also up >150%.
Q2 product revenues up 38% sequentially; Aurix brand up >30% sequentially.
Q2 net operating loss ~$167K, improved ~$280K vs Q1 2026.
Amended loan: interim funding $675K, $325K remaining under $2M commitments; option to increase borrowings Sept 30, 2026.
Reimbursement fee milestone achieved under Smith+Nephew distribution agreement; payment expected this quarter.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.